Mitant 25mg Capsule

Introduction

Mitant is a prescription medication that contains the active ingredient Sunitinib. It is available under the brand name Mitant. This medication is primarily used for the treatment of certain types of cancer, including gastrointestinal stromal tumors (GISTs) and advanced renal cell carcinoma (RCC).

Uses

Mitant is prescribed to patients with specific types of cancer. It is commonly used to treat gastrointestinal stromal tumors (GISTs), which are tumors that develop in the gastrointestinal tract. Additionally, it is also used for the treatment of advanced renal cell carcinoma (RCC), a form of kidney cancer that has spread beyond the kidney.

Dosage and Administration

The dosage of Mitant may vary depending on the specific condition being treated and individual patient factors. Follow the dosage instructions provided by your healthcare professional. Typically, Mitant is taken orally, with or without food. Swallow the capsule whole with a glass of water. Do not crush or chew the capsule.

Mechanism of Action

Mitant contains Sunitinib, which is classified as a tyrosine kinase inhibitor. It works by blocking the action of abnormal proteins that promote the growth of cancer cells. By inhibiting these proteins, Mitant helps to slow down or stop the growth and spread of cancer cells in the body.

Side Effects

Common side effects may include fatigue, nausea, vomiting, diarrhea, loss of appetite, and changes in taste. Inform your healthcare professional if these side effects persist or worsen.

In some cases, Mitant may cause more serious side effects. These can include high blood pressure, heart problems, liver problems, bleeding problems, thyroid problems, and skin reactions. If you experience any severe or persistent side effects, seek immediate medical attention.

Drug Interactions

Mitant may interact with other medications, including over-the-counter medications, herbal supplements, and vitamins. Inform your healthcare professional about all the medications you are taking to avoid potential drug interactions. Some medications may increase the risk of side effects or reduce the effectiveness of Mitant.

Precautions

Before taking Mitant, discuss your medical history and any existing health conditions with your healthcare professional. Inform them about any allergies, liver problems, heart problems, bleeding problems, or thyroid problems you may have. Mitant may not be suitable for everyone, and certain precautions should be taken.

Mitant should not be taken by pregnant women or women planning to become pregnant, as it may harm the unborn baby. Use effective contraception during treatment and for a period of time after discontinuing the medication.

Storage

Patient Tips

• Follow the dosage instructions provided by your healthcare professional.
• Take Mitant with a full glass of water.
• Do not crush or chew the capsule.
• If you experience any severe or persistent side effects, seek immediate medical attention.
• Inform your healthcare professional about all medications you are taking to avoid potential drug interactions.
• Use effective contraception if you are of childbearing age and taking Mitant.
• Store the medication at room temperature, away from moisture and heat.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Sunitinib 12.5 mg hard capsules (Health Professionals SmPC) Available at:
• Sunitinib (Drugs.com) [Accessed 5 Jun. 2024] (online) Available at:
• sunitinib 50 mg capsule antineoplastic – protein-tyrosine kinase inhibitors (RX) [Accessed 3 Jun. 2024] (online) Available at:
• Sunitinib (MedlinePlus) [Accessed 1 Jun. 2024] (online) Available at:
• Jin J, Xie Y, Zhang JS, Wang JQ, Dai SJ, He WF, Li SY, Ashby CR Jr, Chen ZS, He Q. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023 Mar;67:100929. doi: 10.1016/j.drup.2023.100929. Epub 2023 Jan 17. [Accessed 24 Jun. 2024] Available at: